{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:16:08Z","timestamp":1787008568068,"version":"build-2736575974"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nusinersen (Spinraza\u00ae) improves survival of infants with hereditary proximal spinal muscular atrophy and motor function in children up to 12 years. Population-based assessments of treatment efficacy are limited and confined to select cohorts of patients. We performed a nationwide, population-based, single-centre cohort study in children with spinal muscular atrophy younger than 9.5 years at start of treatment in line with reimbursement criteria in the Netherlands. We assessed age-relevant motor function scores, the need for tube feeding, hours of ventilatory support and documented adverse events. We used linear mixed modelling to assess treatment effects. We compared motor function during treatment with natural history data and to individual trajectories of muscle strength and motor function before the start of treatment. We included 71 out of 72 Dutch children who were treated (median age 54 months; range 0\u2013117) and followed them for a median of 38 months (range 5\u201352). We observed improvement of motor function in 72% and stabilization in another 18% of the symptomatic children, which differed from the natural disease course in a matched cohort of which we had previously collected natural history data. Longitudinal analysis showed that motor function improved up to a median of 24 months (range 12\u201330) of treatment after which it stabilized. Shorter disease duration at start of treatment resulted in better treatment efficacy (P &amp;lt; 0.01). Sixteen children (23%) achieved new motor milestones. Bulbar and respiratory function did not improve significantly during treatment. In 15 patients from whom treatment-na\u00efve data were available, the pre-treatment trajectory of motor function decline changed to stabilization or improvement after the start of treatment. We documented 82 adverse events after 934 injections (9%) in 45 patients. None of the adverse events led to treatment discontinuation. Intrathecal nusinersen treatment is safe and improves or stabilizes motor function in 90% of young children with spinal muscular atrophy types 1c\u20133a. We did not observe improvement of respiratory and bulbar functions.<\/jats:p>","DOI":"10.1093\/braincomms\/fcac269","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T17:56:35Z","timestamp":1666893395000},"source":"Crossref","is-referenced-by-count":51,"title":["Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1526-045X","authenticated-orcid":false,"given":"F\u00e9line E V","family":"Scheijmans","sequence":"first","affiliation":[{"name":"Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, 3584 CX, Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Cuppen","sequence":"additional","affiliation":[{"name":"Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, 3584 CX, Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben P A","family":"van Eijk","sequence":"additional","affiliation":[{"name":"Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, 3584 CX, Utrecht , The Netherlands"},{"name":"Biostatistics and Research Support, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht , 3584 CX, Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3661-0962","authenticated-orcid":false,"given":"Camiel A","family":"Wijngaarde","sequence":"additional","affiliation":[{"name":"Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, 3584 CX, Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja A G C","family":"Schoenmakers","sequence":"additional","affiliation":[{"name":"Child Development and Exercise Center, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht, 3584 CX, Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny R","family":"van der Woude","sequence":"additional","affiliation":[{"name":"Child Development and Exercise Center, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht, 3584 CX, Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Bartels","sequence":"additional","affiliation":[{"name":"Child Development and Exercise Center, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht, 3584 CX, Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther S","family":"Veldhoen","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit, Wilhelmina Children\u2019s Hospital , 3584 EA, Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene L B","family":"Oude Lansink","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Physical Therapy Science and Sports, UMC Utrecht Brain Center, University Medical Center Utrecht , 3584 CX, Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2330-9444","authenticated-orcid":false,"given":"Ewout J N","family":"Groen","sequence":"additional","affiliation":[{"name":"Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, 3584 CX, Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fay-Lynn","family":"Asselman","sequence":"additional","affiliation":[{"name":"Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, 3584 CX, Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0339-5506","authenticated-orcid":false,"given":"Renske I","family":"Wadman","sequence":"additional","affiliation":[{"name":"Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, 3584 CX, Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Ludo","family":"van der Pol","sequence":"additional","affiliation":[{"name":"Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, 3584 CX, Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"issue":"1","key":"2022111113430835200_fcac269-B1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"14","key":"2022111113430835200_fcac269-B2","doi-asserted-by":"crossref","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","article-title":"Muscle strength hand motor function in adolescents and adults with spinal muscular atrophy","volume":"95","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"2022111113430835200_fcac269-B3","doi-asserted-by":"crossref","first-page":"365\u2013","DOI":"10.1136\/jnnp-2016-314292","article-title":"Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0\u20134","volume":"88","author":"Wadman","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2022111113430835200_fcac269-B4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archneurol.2010.373","article-title":"Observational study of spinal muscular atrophy type 2 and 3: Functional outcomes over 1 year","volume":"68","author":"Kaufmann","year":"2011","journal-title":"Arch Neurol"},{"issue":"15","key":"2022111113430835200_fcac269-B5","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","article-title":"Population-based analysis of survival in spinal muscular atrophy","volume":"94","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"2022111113430835200_fcac269-B6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"issue":"5","key":"2022111113430835200_fcac269-B7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: Controversies and challenges","volume":"11","author":"Mercuri","year":"2012","journal-title":"Lancet Neurol"},{"key":"2022111113430835200_fcac269-B8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldkotter","year":"2002","journal-title":"Am J Hum Genet"},{"key":"2022111113430835200_fcac269-B9","first-page":"1","article-title":"Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy","author":"Wadman","year":"2020;2(2)","journal-title":"Brain Commun"},{"issue":"18","key":"2022111113430835200_fcac269-B10","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"2022111113430835200_fcac269-B11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2022111113430835200_fcac269-B12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejpn.2017.11.001","article-title":"Single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1","volume":"22","author":"Pechmann","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"2022111113430835200_fcac269-B13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: A non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"issue":"2","key":"2022111113430835200_fcac269-B14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mus.26769","article-title":"Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience","volume":"61","author":"Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"},{"key":"2022111113430835200_fcac269-B15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejpn.2020.05.002","article-title":"Efficacy in nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients","volume":"27","author":"Szabo","year":"2020","journal-title":"Eur J Pediatr Neurol"},{"key":"2022111113430835200_fcac269-B16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of nusinersen after one year of treatment in 123 children with SMA type or 2: A French real-life observational study","volume":"15","author":"Audic","year":"2020","journal-title":"Orphanet J Rare Dis."},{"key":"2022111113430835200_fcac269-B17","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2020-323822","article-title":"Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3.","author":"Maggi","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022111113430835200_fcac269-B18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00415-020-10223-9","article-title":"Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4","volume":"268","author":"De Wel","year":"2021","journal-title":"J Neurol."},{"issue":"3","key":"2022111113430835200_fcac269-B19","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1212\/CPJ.0000000000001033","article-title":"Nusinersen treatment in adults with spinal muscular atrophy","volume":"11","author":"Duong","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"2022111113430835200_fcac269-B20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with nusinersen: A critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2022111113430835200_fcac269-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286420907803","article-title":"Experiences from treating seven adult 5q spinal muscular atrophy patients with nusinersen","volume":"13","author":"Jochmann","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"2022111113430835200_fcac269-B22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3\u2014A prospective observational study","volume":"6","author":"Walter","year":"2019","journal-title":"J Neuromuscul Dis."},{"key":"2022111113430835200_fcac269-B23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nmd.2020.12.006","article-title":"Nusinersen treatment of older children and adults with spinal muscular atrophy","volume":"31","author":"Konersman","year":"2021","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"2022111113430835200_fcac269-B24","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/acn3.51411","article-title":"Nusinersen in pediatric and adult patients with type III spinal muscular atrophy","volume":"8","author":"Pera","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"2022111113430835200_fcac269-B25","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.nmd.2021.03.012","article-title":"Age related treatment effect in type II spinal muscular atrophy pediatric patients treated with nusinersen","volume":"31","author":"Coratti","year":"2021","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"2022111113430835200_fcac269-B26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/acn3.51276","article-title":"Type I SMA \u201cnew natural history\u201d: Long-term data in nusinersen-treated patients","volume":"8","author":"Pane","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"2022111113430835200_fcac269-B27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The children\u2019s hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): Test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2022111113430835200_fcac269-B28","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/PEP.0b013e3182351f04","article-title":"Validation of the children\u2019s hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND)","volume":"23","author":"Glanzman","year":"2011","journal-title":"Pediatr Phys Ther"},{"issue":"1","key":"2022111113430835200_fcac269-B29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/mus.25705","article-title":"Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological exam\u2014Part 2: Experience from a nusinersen clinical study","volume":"57","author":"Bishop","year":"2018","journal-title":"Muscle Nerve"},{"issue":"9\u201310","key":"2022111113430835200_fcac269-B30","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith functional motor scale for SMA II and III patients","volume":"17","author":"O\u2019Hagen","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"2022111113430835200_fcac269-B31","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1177\/0883073811420294","article-title":"Validation of the expanded Hammersmith functional motor scale in spinal muscular atrophy type II and III","volume":"26","author":"Glanzman","year":"2011","journal-title":"J Child Neurol."},{"issue":"SUPPL. 450","key":"2022111113430835200_fcac269-B32","first-page":"86","article-title":"WHO Motor development study: Windows of achievement for six gross motor development milestones. Acta paediatrica","volume":"95","author":"Whomrgs","year":"2006","journal-title":"Int J Paediatr"},{"key":"2022111113430835200_fcac269-B33"},{"key":"2022111113430835200_fcac269-B34","author":"EMA"},{"key":"2022111113430835200_fcac269-B35","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: Double-blind, randomized, placebo-controlled tiral of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS ONE"},{"key":"2022111113430835200_fcac269-B36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: Final report of a phase 2, open-label, multicentre, dose-escalation study","volume":"5","author":"Finkel","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"2022111113430835200_fcac269-B37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study","volume":"63","author":"Ascadi","year":"2021","journal-title":"Muscle Nerve"},{"key":"2022111113430835200_fcac269-B38"},{"key":"2022111113430835200_fcac269-B39","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1111\/ene.14472","article-title":"Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy","volume":"27","author":"Stolte","year":"2020","journal-title":"Eur J Neurol"},{"key":"2022111113430835200_fcac269-B40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","article-title":"Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","author":"Pera","year":"2017","journal-title":"BMC Neurol"},{"key":"2022111113430835200_fcac269-B41","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.nmd.2017.01.018","article-title":"Disease impact on general well-being and therapeutic expectations of European type II and type III spinal muscular atrophy patients","volume":"27","author":"Rouault","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"2022111113430835200_fcac269-B42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"2022111113430835200_fcac269-B43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/PEP.0000000000000515","article-title":"Quantitative evaluation of lower extremity joint contractures in spinal muscular atrophy: Implications for motor function","volume":"30","author":"Salazar","year":"2018","journal-title":"Pediatr Phys Ther"},{"key":"2022111113430835200_fcac269-B44","article-title":"Motor unit gains in treated spinal muscular atrophy patients","author":"Sumner","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022111113430835200_fcac269-B45","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"2022111113430835200_fcac269-B46","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"2022111113430835200_fcac269-B47"},{"issue":"3","key":"2022111113430835200_fcac269-B48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JND-190465","article-title":"Feeding and swallowing problems in infants with spinal muscular atrophy type 1: An observational study","volume":"7","author":"Van der Heul","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"2022111113430835200_fcac269-B49","first-page":"83","article-title":"Maximum bite force in patients with spinal muscular atrophy during the first year of nusinersen therapy\u2014A pilot study","volume":"XXXIX","author":"Kruse","year":"2020","journal-title":"Acta Myol"},{"key":"2022111113430835200_fcac269-B50","doi-asserted-by":"crossref","DOI":"10.1111\/ped.13931","article-title":"Respiratory assessment in a spinal muscular atrophy infant treated with nusinersen","author":"Ogawa","year":"2019","journal-title":"Pediatr Int"},{"key":"2022111113430835200_fcac269-B51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ppul.25140","article-title":"Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience","volume":"56","author":"Lavie","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2022111113430835200_fcac269-B52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","article-title":"Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen","volume":"219","author":"Sansone","year":"2020","journal-title":"J Pediatr"},{"key":"2022111113430835200_fcac269-B53","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ppul.25142","article-title":"Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen","volume":"56","author":"G\u00f3mez-Garc\u00eda de la Banda","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2022111113430835200_fcac269-B54","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216564","article-title":"Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3","author":"Chacko","year":"2022","journal-title":"Thorax"},{"key":"2022111113430835200_fcac269-B55","doi-asserted-by":"publisher","DOI":"10.1111\/ped.14510","article-title":"Nusinersen improved respiratory function in spinal muscular atrophy type 2","author":"Tanaka","year":"2021","journal-title":"Pediatr Int"},{"key":"2022111113430835200_fcac269-B56","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/brainsci11091244","article-title":"Assessment of bulbar function in adult patients with 5q-SMA type 2 and 3 under treatment with nusinersen","volume":"11","author":"Brakemeier","year":"2021","journal-title":"Brain Sci"},{"key":"2022111113430835200_fcac269-B57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejpn.2021.02.007","article-title":"Nusinersen does not improve lung function in a cohort of children with spinal muscular atrophy e A single-center retrospective study","volume":"31","author":"Heitscmidt","year":"2021","journal-title":"Eur J Paediatr Neurol."},{"issue":"5","key":"2022111113430835200_fcac269-B58","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00234-019-02189-x","article-title":"Radiation exposure of image-guided intrathecal administration of nusinersen to adult patients with spinal muscular atrophy","volume":"61","author":"Oldenburg","year":"2019","journal-title":"Neuroradiology"},{"issue":"10","key":"2022111113430835200_fcac269-B59","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1097\/BPO.0000000000001247","article-title":"Preliminary safety and tolerability of a novel subcutaneous intrathecal catheter system for repeated outpatient dosing of nusinersen to children and adults with spinal muscular atrophy","volume":"38","author":"Strauss","year":"2018","journal-title":"J Pediatr Orthop"},{"issue":"15","key":"2022111113430835200_fcac269-B60","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1212\/WNL.0000000000006006","article-title":"Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy","volume":"91","author":"Veerapandiyan","year":"2018","journal-title":"Neurology"},{"issue":"12","key":"2022111113430835200_fcac269-B61","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s00247-018-4206-9","article-title":"A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy","volume":"48","author":"Mousa","year":"2018","journal-title":"Pediatr Radiol"},{"issue":"1","key":"2022111113430835200_fcac269-B62","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00247-018-4240-7","article-title":"Ultrasound-guided cervical puncture for nusinersen administration in adolescents","volume":"49","author":"Ortiz","year":"2019","journal-title":"Pediatr Radiol"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcac269\/46700020\/fcac269.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/6\/fcac269\/46959590\/fcac269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/6\/fcac269\/46959590\/fcac269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T09:31:38Z","timestamp":1668159098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcac269\/6783135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcac269","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,10,31]]},"article-number":"fcac269"}}